Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Proteus, LLC, also known as Proteus Venture Partners, is a boutique investment and advisory firm founded in 2006 and based in Portola Valley, California. The firm is recognized as one of the first dedicated venture capital firms focusing exclusively on regenerative medicine. Their investment strategy encompasses a wide range of areas within regenerative medicine, including cell therapy, tissue engineering, small molecule drugs, biologics, and aesthetic medicine.
Proteus has a historical fund size of $225 million, targeting investments ranging from $10 million to $20 million per company. The firm has planned to make 10 to 15 investments per fund, reflecting a selective approach to funding. Although their first fund has been liquidated, Proteus is currently raising a new early-stage venture fund focused on regenerative medicines.
The firm operates globally, with a particular emphasis on the Bay Area and international markets. Proteus not only provides capital but also consulting and advisory services, leveraging their expertise and network to support portfolio companies in the regenerative medicine sector.
Proteus, LLC focuses on regenerative medicine, which includes a variety of sectors such as cell therapy, tissue engineering, small molecule drugs, biologics, and medical devices. Their investment strategy is stage-agnostic, allowing them to invest in companies ranging from academia spinouts to public companies involved in clinical trials. This flexibility enables Proteus to engage with a diverse array of companies at different stages of development.
The firm targets investments in both early-stage and established companies, reflecting a commitment to advancing innovations in regenerative medicine. Proteus has a global geographic focus, which includes not only North America but also international markets. They also collaborate with governmental organizations on initiatives related to regenerative medicine, further broadening their impact in the field.
While specific portfolio companies are not publicly available, Proteus has historically focused on investments in regenerative medicine sectors. This includes strategies related to cord blood banking and therapeutics, which are critical areas within the regenerative medicine landscape. The firm has positioned itself as a key player in funding innovations that aim to transform healthcare through advanced therapies.
Proteus's investment approach has included a variety of companies involved in cell therapy and tissue engineering, reflecting their commitment to supporting groundbreaking advancements in these fields. Their portfolio strategy emphasizes both early-stage ventures and established companies, ensuring a comprehensive engagement with the regenerative medicine market.
Gregory Bonfiglio — Founder & Managing Partner. Bonfiglio has a background in venture capital with prior experience at Anthem Venture Partners. He is actively involved in the regenerative medicine community, serving on advisory boards such as BioBridge Global and participating in various regenerative medicine conferences.
Daniel Kraft — Venture Partner. Kraft is known for his work with Singularity University and Exponential Medicine, bringing a wealth of knowledge in innovation and technology to the firm.
As of 2025, Proteus, LLC reported an annual revenue of $5 million. The firm is currently in the process of raising a new early-stage venture fund focused on regenerative medicines, although specific details about recent investments or exits remain limited.
Proteus's first fund, which targeted a size of $225 million, has been liquidated, and there is no public evidence of a successor fund or recent fund deployment. The firm has been noted for its advisory work alongside direct investments, suggesting a potential shift in focus.
What are Proteus's investment criteria?
Proteus invests in companies focused on regenerative medicine, including sectors like cell therapy, tissue engineering, and small molecule drugs. They are stage-agnostic, meaning they consider investments from early-stage startups to established public companies.
How can I pitch to Proteus?
Founders interested in pitching to Proteus should prepare a detailed presentation that outlines their business model, market potential, and how their innovation fits within the regenerative medicine sector. While specific application forms are not mentioned, a well-structured deck is essential.
What makes Proteus different from other venture capital firms?
Proteus is distinguished by its exclusive focus on regenerative medicine, making it one of the first dedicated firms in this space. Their combination of capital investment and advisory services provides a unique value proposition for portfolio companies.
What is the geographic scope of Proteus's investments?
Proteus has a global investment focus, with a particular emphasis on the Bay Area and international markets. This broad geographic reach allows them to tap into diverse innovations in regenerative medicine.
What is the typical check size for Proteus's investments?
Proteus typically invests between $10 million and $20 million per company, reflecting their strategy to support significant innovations in the regenerative medicine field.
What kind of support does Proteus provide to its portfolio companies?
In addition to capital, Proteus offers consulting and advisory services, leveraging their expertise and network to help portfolio companies navigate the complexities of the regenerative medicine industry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.